跳转至内容
Merck

N3539

Sigma-Aldrich

尼可地尔

≥98% (HPLC)

别名:

2-(吡啶-3-羰基氨基)乙基硝酸酯, 2-烟酰胺基硝酸乙酯, N-[2-硝氧乙基]-3-吡啶键酰胺, SG-75, 尼可地尔, 烟浪丁

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H9N3O4
CAS号:
分子量:
211.17
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to off-white

溶解度

DMSO: >10 mg/mL

儲存溫度

room temp

SMILES 字串

[O-][N+](=O)OCCNC(=O)c1cccnc1

InChI

1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)

InChI 密鑰

LBHIOVVIQHSOQN-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

應用

尼古拉地尔已被用作钾(K +)通道激活剂和电压门控钙通道抑制剂,用于研究其对人类长QT综合征2(LQTS2)诱导的多能干细胞(hiPSCs)衍生的心肌细胞动作电位(action potential)的影响。

生化/生理作用

尼可地尔是一种杂合ATP敏感性K+(KATP)通道开放剂,也是烟酰胺硝酸盐NO供体。尼可地尔能够选择性激活含有SUR2B-和SUR2A-的KATP通道。它可以增强内皮NO合酶的表达,并防止缺血性室性心律失常。尼可地尔通过激活钾离子通道并提供一氧化氮激活鸟苷酸环化酶,引起GMP活化,从而导致动脉和静脉血管舒张。尼可地尔对血管钾离子通道具有选择性,但对心肌收缩和传导没有明显作用。
尼可地尔(Nicorandil )具有心脏保护作用。

特點和優勢

该化合物在受体分类和信号转导手册的钾通道页面上有重点介绍。想要浏览手册的其他页面, 请单击此处

象形圖

FlameExclamation mark

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 4 Oral - Org. Perox. D

儲存類別代碼

5.2 - Organic peroxides and self-reacting hazardous materials

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

L Toquero et al.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 8(8), 717-720 (2006-09-15)
Use of Nicorandil in the treatment of ischaemic heart disease has been associated with oral, ileal and more recently anal ulceration. We report a series of six cases of peri-anal ulceration in patients on nicorandil therapy, their response to withdrawal
A Markham et al.
Drugs, 60(4), 955-974 (2000-11-21)
Nicorandil is a drug with both nitrate-like and ATP-sensitive potassium-channel (K+ ATP) activating properties. By virtue of this dual mechanism of action, the drug acts as a balanced coronary and peripheral vasodilator and reduces both preload and afterload. The K+
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure.
Amala A Louis et al.
European journal of heart failure, 4(1), 111-116 (2002-01-29)
Lamiaa A Ahmed et al.
Biochemical pharmacology, 86(9), 1301-1310 (2013-07-23)
Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers. In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration
Shigeo Horinaka
Drugs, 71(9), 1105-1119 (2011-06-30)
Nicorandil, a unique dual pharmacological mechanism anti-anginal agent with adenosine triphosphate sensitive potassium (K(ATP)) channel agonist and nitrate-like properties, provides cardiologists with a means of managing angina pectoris patients effectively and provides long-term cardioprotection. The aim of this review is

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门